Call of Duty SVP and General Manager Johanna Faries sits down with Yahoo Finance Live to discuss the launch of "Call of Duty: Warzone 2.0" battle royale mode, "Call of Duty: Modern Warfare II"'s launch weekend, and the game's community. Read More...
Motley Fool
Why Editas Medicine’s Shares Are Falling Thursday
Shares of Editas Medicine (NASDAQ: EDIT) were down as much as 21% at one point on Thursday. Editas has a 52-week low of $9.59 and a 52-week high of $37.50, and is down more than 60% so far this year. The clinical-stage biotech, which seeks therapies through CRISPR gene-editing, paused its Brilliance Phase 1/2 trial for its lead therapy, EDIT-101, to treat the rare eye disease, leber congential amaurosis (LCA) 10, that affects the retina.
